Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in Leukaemia by Maher, Michael et al.
MINI REVIEW
published: 24 September 2018
doi: 10.3389/fgene.2018.00405
Frontiers in Genetics | www.frontiersin.org 1 September 2018 | Volume 9 | Article 405
Edited by:
Carles Canto,




San Raffaele Hospital (IRCCS), Italy
Beisi Xu,






This article was submitted to
Epigenomics and Epigenetics,
a section of the journal
Frontiers in Genetics
Received: 29 June 2018
Accepted: 03 September 2018
Published: 24 September 2018
Citation:
Maher M, Diesch J, Casquero R and
Buschbeck M (2018)
Epigenetic-Transcriptional Regulation





Regulation of Fatty Acid Metabolism
and Its Alterations in Leukaemia
Michael Maher 1, Jeannine Diesch 1, Raquel Casquero 1 and Marcus Buschbeck 1,2*
1 Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol-Universitat Autònoma de
Barcelona, Barcelona, Spain, 2 Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research
Institute (PMPPC-IGTP), Barcelona, Spain
In recent years fatty acid metabolism has gained greater attention in haematologic
cancers such as acute myeloid leukaemia. The oxidation of fatty acids provides fuel
in the form of ATP and NADH, while fatty acid synthesis provides building blocks for
cellular structures. Here, we will discuss how leukaemic cells differ from healthy cells
in their increased reliance on fatty acid metabolism. In order to understand how these
changes are achieved, we describe the main pathways regulating fatty acid metabolism
at the transcriptional level and highlight the limited knowledge about related epigenetic
mechanisms. We explore these mechanisms in the context of leukaemia and consider
the relevance of the bone marrow microenvironment in disease management. Finally, we
discuss efforts to interfere with fatty acid metabolism as a therapeutic strategy along with
the use of metabolic parameters as biomarkers.
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INTRODUCTION
Acute myeloid leukaemia (AML) is a group of disorders affecting the myeloid lineage of blood
cells in the bone marrow. Blood cells are formed in the bone marrow where they originate
from haematopoietic stem cells (HSC). In AML, HSCs undergo genetic mutations that result in
ineffective haematopoiesis and dysfunctional blood cells due to impaired differentiation (Shih et al.,
2012). These leukaemia stem cells show spontaneous apoptosis in vitro but increased proliferation
in vivo (Lane et al., 2009), indicating that intrinsic factors of the cells and extrinsic factors in the
bone marrow environment may contribute to their survival. AML cells can be characterised by
aberrant genetic and epigenetic changes that distinguish them from healthy cells (Metzeler et al.,
2016; Wouters and Delwel, 2016; Fisher et al., 2017). It has been well documented that cancer cells,
including AML, can also be distinguished metabolically from normal cells (Kohli and Passegué,
2014; Berger et al., 2017). Otto Warburg proposed that cancer cells exhibit increased glycolysis in
the presence of oxygen (Warburg effect), thereby providing the cells with a more readily accessible
source of ATP (Warburg, 1956). Initially, this idea led researchers to think of cancer in terms
of metabolic dysfunction due to mitochondrial injury. Instead, what is becoming evident is that
metabolic plasticity may be a cellular adaption to increased energy demands of proliferating cells in
a harsh tumour microenvironment in which there may be limited nutrient and oxygen supply.
These unfavourable conditions require cancer cells to modulate their metabolism to one that
promotes survival and proliferation, which in turn may lead to drug resistance (Ma et al., 2018).
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Dysregulation of fatty acid (FA) metabolism has been
implicated in a variety of diseases and a prominent role in
cancer is emerging. FA synthesis is required for anabolic reactions
such as membrane biosynthesis and generation of signalling
molecules. From the oxidation of FAs, ATP yield is more than
twice that of glucose or amino acids, making FAs an important
fuel. This review endeavours to highlight the changes in lipid
metabolism that distinguish malignant AML cells from normal,
healthy cells. Firstly, to give some background, we provide
a summary of anabolic and catabolic FA metabolism and an
overview of key transcriptional regulators. We also present and
discuss relevant epigenetic regulators and the reciprocal effects of
FA metabolism on epigenetic mechanisms.
FA METABOLISM
FA Synthesis and the Storage of
High-Energy Fuel
Lipids originate from dietary sources or are generated by
de novo FA biosynthesis occurring mainly in the liver and
adipose tissue (reviewed in Salati and Goodridge, 1996). Acetyl-
CoA is the precursor of FA synthesis and is produced in
the mitochondria from FA oxidation (Figure 1). Acetyl-CoA is
converted within the tricarboxylic acid (TCA) cycle to citrate
and subsequently transported into the cytoplasm by the citrate
transporter. In the cytoplasm, citrate is cleaved by citrate
lyase regenerating acetyl-CoA that can then be used for FA
synthesis. The first and rate-limiting step of FA synthesis is the
ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA
catalyzed by acetyl-CoA-carboxylase 1 (ACC1). The remaining
steps are catalyzed by the FA synthase (FAS) complex, which leads
to a series of reactions until the 16-carbon FA palmitic acid, is
synthesised. Further elongation and desaturation takes place at
the endoplasmatic reticulum membrane (Salati and Goodridge,
1996).
ACC exists in two isoforms, ACC1 and ACC2 (Abu-Elheiga
et al., 1997), and is activated by citrate and inhibited by palmitoyl-
CoA and malonyl-CoA by allosteric regulation (Trumble et al.,
1995). Further, both ACC isoforms are phosphorylated by AMP-
activated protein kinase (AMPK), an important cellular sensor
of low energy states, which leads to their inhibition (Munday
et al., 1988; Winder et al., 1997). Conversely, prolyl hydroxylase 3
(PHD3) activates ACC2 via proline hydroxylation (German et al.,
2016). In addition to the short-term and transient regulation
through post-translational modifications, long-termmechanisms
include changes in expression of genes encoding key FA synthesis
enzymes and occur in response to dietary factors. For instance,
consuming a carbohydrate-rich diet increases ACC1 and FAS
expression, which then promotes FA formation (Kim, 1997).
Conversely, fasting decreases FA synthesis by inhibiting ACC1
and FAS expression (Pape et al., 1988).
ß-Oxidation
FAs are degraded by ß-oxidation in the mitochondria providing
energy in the form of ATP and acetyl-CoA for protein
acetylation and anabolic reactions. Several membrane-
associated proteins including CD36, membrane-associated
FA-binding proteins (FABP) and a number of FA transport
proteins facilitate FA uptake into the cell (Stremmel et al.,
2001). In particular, CD36 plays an important role in the
regulation of FA uptake due to its ability to translocate between
intracellular endosomes and the plasma membrane. This
intracellular translocation is dependent on FA availability,
the energy status of the cell (Luiken et al., 2003) as well as
CD36 transcriptional activation (Bastie et al., 2005). Once in
the cell, FAs undergo conversion into long-chain acyl-CoA
catalysed by fatty acyl-CoA synthase. Acyl-CoA is transported
into the mitochondria by the carnitine palmitoyltransferases,
CPT1 and CPT2, that are located at the outer and inner
mitochondrial membranes, respectively (McGarry et al., 1977).
Acyl-CoA is subsequently converted into acetyl-CoA through
ß-oxidation, which then enters the TCA cycle (Kunau et al.,
1995). ß-oxidation is inversely coupled to FA synthesis and
regulated by ACC2-derived malonyl-CoA, which inhibits
mitochondrial FA uptake by CPT1. Conversely, malonyl-
CoA decarboxylase decreases the inhibition of CPT1 by
decarboxylating malonyl-CoA to acetyl-CoA, leading to an
elevated rate of FA oxidation (McGarry et al., 1977; Ruderman
and Dean, 1998). Importantly, ß-oxidation enzymes are
susceptible to negative feedback inhibition in which the
intermediates they produce inhibit their activity (Kunau et al.,
1995).
Transcriptional Regulation of FA
Metabolism
Both anabolic and catabolic processes of FA metabolism are
under the control of transcription factors (TFs) (Figure 2).
Peroxisome proliferator-activated receptors (PPAR) are key TFs
involved in increased FA oxidation (reviewed in Poulsen et al.,
2012). PPARs act as heterodimers with retinoid X receptor
(RXR) and are activated by binding DNA and FA ligands
(Forman et al., 1997; Aagaard et al., 2011; Poulsen et al., 2012).
PPARα and PPARß/δ are involved in increased FA uptake and
activation of mitochondrial ß-oxidation in various cell types,
while PPARγ is mainly expressed in adipose tissue and is a potent
inducer of adipogenesis (reviewed in Poulsen et al., 2012). FA
metabolism genes that are induced by PPARs include CD36,
FATP, acyl-CoA synthetase, malonyl-CoA decarboxylase and
CPT1 (reviewed in Desvergne and Wahli, 1999; Mandard et al.,
2004). Likewise, peroxisome proliferator-activated receptor-
gamma co-activator alpha (PGC-1α) is involved in increased
overall FA oxidation as well as mitochondrial biogenesis. AMPK
and sirtuin 1 (SIRT1) activate PGC-1α through phosphorylation
and deacetylation, respectively, in response to low energy
sources (Rodgers et al., 2005; Jäger et al., 2007). PGC-1α is a
potent activator and a target of several other metabolism-related
TFs involved in the up-regulation of oxidative metabolism,
including PPARα and PPAR∂ (Vega et al., 2000), forkhead box
protein O1 (FOXO1; Puigserver et al., 2003), nuclear respiratory
factors (NRF1 and NRF2; Wu et al., 1999), as well as the
lipogenic regulator, carbohydrate-responsive element-binding
protein (ChREBP; Chambers et al., 2013). FOXO1 enhances
FA oxidation by increasing expression of acyl-CoA oxidase and
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FIGURE 1 | A schematic representation of fatty acid (FA) metabolism. Long chain FAs, such as palmitic acid, are actively transported across the cell membrane by
membrane-bound transporters, such as CD36 and FA transport protein (FATP). FA binding proteins (FABPpm, membrane-associated; FATP, cytosolic) facilitate the
transfer. In the cytosol, FAs can either be stored in lipid droplets or undergo enzymatic conversion to FA-acyl-CoA that can enter the mitochondria via the carnitine
palmitoyltransferases 1 and 2 (CPT1, CPT2) transporters, located on the outer and inner mitochondrial membranes, respectively. The activation of CPT1 is a survival
signal and inhibits the oligomerisation of the pro-apoptotic Bcl-2 family proteins, Bak, and Bax. Inside mitochondria, FA-acyl-CoA molecules are broken down in a
series of enzymatic reactions known as ß-oxidation. FADH2 and NADH are released and are used as co-factors in the electron transport chain (ETC) to produce ATP.
Acetyl-CoA is released and enters the tricarboxylic acid cycle (TCA), where it is oxidised for citrate production. Citrate is transported to the cytosol where it is
converted to acetyl-CoA. Acetyl-CoA carboxylase 1 (ACC1) –mediated conversion of acetyl-coA to malonyl-CoA is the rate-limiting step in fatty acid synthesis.
Malonyl-CoA in particular when produced by ACC2, inhibits CPT1 and thus limits ß-oxidation.
PPARδ, repressing ACC2 and by promoting FA uptake through
translocation of CD36 to the plasma membrane (Bastie et al.,
2005). NRF1 and NRF2 are principal promoters of mitochondrial
biogenesis and thus increase the β-oxidation capacity of the
cell (Scarpulla, 1997). NRF1 further regulates several FA
oxidation regulators such as PPARα, Lipin1, and PGC-1ß
(Hirotsu et al., 2012).
Anabolic regulators of FA metabolism play a role in
countering the effects of higher oxidation in times of plentiful
nutrient supply by increasing FA synthesis and storage.
A build up of FAs or cholesterol can be toxic to cells
and so feedback loops are in place to control intracellular
levels. Sterol regulatory element-binding proteins (SREBP)
are required for the control of de novo FA and cholesterol
synthesis (Bengoechea-Alonso and Ericsson, 2007; Espenshade
and Hughes, 2007). SREBPs are bound to the endoplasmic
reticulum from where they translocate to the nucleus in response
to depleted intracellular FA or cholesterol levels (Sakai et al.,
1996). The SREBP-1c isoform has been shown to upregulate
the expression of several genes involved in FA synthesis,
including citrate lyase, ACC1, and FAS (reviewed in Foufelle
and Ferré, 2002). ChREBP is a glucose-responsive TF. Glucose
enhances ChREBP nuclear translocation and DNA binding
by decreasing phosphorylation (Kawaguchi et al., 2001), while
FAs inhibit ChREBP activity (Dentin et al., 2005). Glucose
has been shown to induce ChREBP gene expression in the
liver (Dentin et al., 2004), which in turn induces lipogenic
genes such as ACC1 and FAS (Ishii et al., 2004). Taken
together, both FA synthesis and ß-oxidation are regulated on the
transcriptional level by a range of opposingly acting TFs and
dietary cues.
Interplay Between Epigenetic Regulation
and Fatty Acid Metabolism
While TF-mediated regulation in metabolism is generally
transient, epigenetic factors may confer prolonged alterations,
which can be transmitted to the next generation. Chromatin
modifications comprise the molecular basis of epigenetic
mechanisms, of which DNA methylation is related with gene
silencing (reviewed in Wolffe and Matzke, 1999), and histone
acetylation is associated with gene transcription (Marmorstein
and Zhou, 2014). Isocitrate dehydrogenase 1 (IDH1) mutations
are implicated in AML and other myeloid malignancies. IDH1
inhibition results in reduced α-ketoglutarate (αKG) production,
leading to increased histone methylation, which has been
shown to increase tumour cell differentiation and increase
cells’ therapy response (Calvert et al., 2017). Diets rich in
fat have been shown to affect chromatin accessibility of
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FIGURE 2 | Depicted are the main transcription factors involved in fatty acid (FA) synthesis and FA oxidation. (A) In response to high glucose concentrations,
carbohydrate responsive element-binding protein (ChREBP) is transported to the nucleus. Sterol regulatory element-binding protein (SREBP) is bound to the
endoplasmic reticulum (ER) where it is translocated to the golgi apparatus (GA). SREBP is cleaved to produce its active transcription factor form, a process that is
inhibited by high levels of cholesterol. Both ChREBP and SREBP are involved in FA synthesis by increasing expression of citrate lyase, acetyl-CoA carboxylase (ACC1)
and fatty acid synthase (FAS). (B) The low energy sensors, AMPK and SIRT1, activate peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α),
which after translocation to the nucleus, interacts with several transcription factors: Peroxisome proliferator-activated receptor (PPAR) and retinoid X receptor (RXR),
which heterodimerise upon ligand binding; forkhead box protein O1 (Fox01); and nuclear respiratory factor 1 (NRF1/2). These events result in up-regulation of FA
oxidation by increasing expression of FA transporters and rate-limiting enzymes (CD36, ACC2, acyl-CoA oxidase) and by increasing overall mitochondrial biogenesis.
regulatory gene regions in rodents (Leung et al., 2014). Several
studies in rodent offspring have shown that higher maternal
dietary fat intake caused persistent DNA hypermethylation
and down-regulation of the Fads2 gene, which encodes FA
desaturase in FA synthesis (Niculescu et al., 2011, 2013; Kelsall
et al., 2012). Similar diet-induced epigenetic changes found
in adult rodents could be reversed by decreasing fat intake
(Hoile et al., 2013). Maternal high-fat diet has also been
reported to induce hypermethylation of the PGC-1α promoter
in skeletal muscle cells. Interestingly, the resulting decreased
expression can be counteracted by maternal exercise, further
highlighting the plasticity of FA metabolism (Laker et al.,
2014).
Acetyl-CoA is generated from glucose via glycolysis and
is substrate for histone acetylation (Takahashi et al., 2006).
Indeed, high levels of glucose have been shown to increase
histone acetylation (Wellen and Thompson, 2012), while a
converse reduction in acetyl-CoA synthesis results in rapid
histone deacetylation (Takahashi et al., 2006). In this way,
acetyl-CoA is an important link between energy metabolism
and chromatin regulation (Rathmell and Newgard, 2009;
Wellen and Thompson, 2012). FAs also affect acetyl-CoA
levels and thus histone acetylation. On the one hand, de
novo FA synthesis uses acetyl-CoA as substrate, and therefore
competes with histone acetylation for the same acetyl-CoA
pool. Lowering the rate of FA synthesis, by reducing ACC1
expression, increases global histone acetylation and gene
expression (Galdieri and Vancura, 2012). On the other hand,
stimulating FA oxidation, and thereby increasing acetyl-CoA
levels, leads to increased histone acetylation (McDonnell et al.,
2016). In addition epigenetic factors may also act on non-
chromatin substrates to regulate FA metabolism. This has
been observed in the histone deacetylase 3 (HDAC3) and
SIRT1 inhibition of PPARγ (Qiang et al., 2012; Jiang et al.,
2014).
Interestingly, metabolic enzymes can also more directly
act to bring about changes in chromatin structure and gene
transcription. AMPK has been shown to phosphorylate
H2B histones to activate transcription of AMPK-responsive
genes, such as CPT1c, during metabolic stress (Bungard
et al., 2010). Similarly, AMPK phosphorylation of the
methytransferase enzyme, EZH2, represses polycomb
repressive complex 2 (PRC2) -mediated methylation,
thereby up-regulating tumour suppressor genes (Wan
et al., 2018). Further, it has been reported that almost
all glycolytic enzymes are RNA-binding proteins, thereby
linking metabolism and gene transcription (Beckmann et al.,
2015).
Overall there is complementary interplay between epigenetic
regulation and FA metabolism that is mediated by dietary FAs
directly alteringmethylation states and by the provision of acetyl-
CoA for acetylation.
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THE ROLE OF FA METABOLISM IN
LEUKAEMIA
The Role of Epigenetic Regulation in
Altered FA Metabolism
It is now well accepted that epigenetic changes contribute
to haematological cancers (Pastore and Levine, 2016). Altered
DNA methylation patterns are a hallmark of AML, partly due
to dysregulation of DNA methyltransferase (DNMT)-encoding
genes (reviewed in Wu et al., 1999). During recent years links
between epigenetic regulation and an altered FA metabolism
have been emerging in AML. For instance, FABP4 has a dual
role in increasing FA uptake and signalling to the epigenetic
regulators, which together create a favourable environment for
AML proliferation (Yan et al., 2017). Mechanistically, FABP4 up-
regulation increases IL-6 expression and STAT3 phosphorylation
leading to DNMT1 overexpression and silencing of the cell cycle
inhibitor, p15 (Yan et al., 2017). Conversely, forced DNMT1
expression caused increased FABP4 expression in AML, pointing
towards a possible metabolic-epigenetic feedback loop (Yan et al.,
2018). The epigenetic silencing of the ACC2 gene is a key step
that drives the reliance of AML cells on FA oxidation. Repression
of the ACC2 gene by SIRT1-dependent histone deacetylation
allows for simultaneous ß-oxidation and FA synthesis to take
place (Corbet and Feron, 2017). Simultaneous up-regulation of
lipolysis and dysregulation of lipogenesis has been speculated to
be a potential hallmark of cancer cell metabolism (Carracedo
et al., 2013). Indeed, the ACC2 activator, PHD3, has been shown
to be down-regulated in around 80% of AML patients, resulting
in higher ß-oxidation (German et al., 2016).
Healthy haematopoietic and leukaemia stem cells have been
traditionally identified by immunophenotyping cell markers
(Bennett et al., 1976). However, metabolic heterogeneity among
these cell populations is becoming increasingly evident. CD36-
positive leukaemia stem cells were shown to have elevated
FA uptake and ß-oxidation (Ye et al., 2016). In addition
to increased FA uptake, higher rates of anaerobic glycolysis
contribute to increased ß-oxidation in AML cells by promoting
a decreased electrochemical gradient on the mitochondrial
membrane and uncoupling of the electron transport chain
(Samudio et al., 2010). While we are just at the beginning
of understanding the significance of metabolic changes in
leukaemia, increased reliance on FAs as fuel is becoming
apparent.
The Bone Marrow Is the Nutrient-Providing
HSC Niche
The bone marrow microenvironment provides nutrients and
growth signals to both healthy HSCs and disease clones.
The bone marrow is composed of an array of different cell
types including adipocytes and mesenchymal stem cells and
is the pertinent site of interest in leukaemia (Medyouf, 2017).
Adipocytes account for approximately 70% of the tissue mass
of the bone marrow (Hardaway et al., 2014). AML blasts
undergo spontaneous apoptosis in vitro, but proliferate in vivo
in the bone marrow (Lane et al., 2009), indicating that the
bone marrow environment contributes to extrinsic growth-
promoting factors. Indeed, bonemarrow adipocytes protect acute
monocytic leukaemia cells by disrupting apoptosis. Adipocytes
supply leukaemia cells with FA ligands that induce PPARγ-
controlled FA oxidation genes, thereby promoting cell survival
(Tabe et al., 2017). Further evidence of metabolic cross-talk
involves secreted FABP4 proteins that act as carrier proteins
for FA transport between adipocytes and AML blasts (Shafat
et al., 2017). Adipocytes also produce adipokines such as leptin
and adiponectin, which modulate FA metabolism of nearby
cells (VanSaun, 2013). Interestingly, AML cells also exhibit
higher rates of ß-oxidation when co-cultured with mesenchymal
stem cells (Samudio et al., 2008). A mouse study showing that
osteoblast cells induce leukaemogenesis in HSCs via Fox01 (Kode
et al., 2016). Overall, AML cells manage to take advantage of the
robust growth-promoting environment of the bone marrow.
Interference With Therapy
Allogeneic haematopoietic cell transplantation (alloHCT)
remains the only curative option for AML (Bejanyan et al.,
2015). However, due to the invasive nature of alloHCT and
compounding risk factors of comorbidities, chemotherapies
remain the preferred treatment options for elderly AML
patients (Ustun et al., 2013). Recent studies have indicated that
metabolic changes may confer drug resistance. High oxidative
phosphorylation has been associated with cytarabine (ara-C)–
resistance in leukaemia cells (Farge et al., 2017). Although Ara-C
killed both resting and proliferating cancer cells, the remaining
resistant cells were characterised by increased FA oxidation and
up-regulated CD36. In another study, CD36-positive leukaemia
cells were shown to be relatively more drug-resistant to AraC in
vivo and in vitro compared with CD36-negative cells (Ye et al.,
2016). Moreover, high expression of CD36 and CPT1a recorded
in different cohorts of AML patients was associated with poor
prognosis and shorter overall survival (Perea et al., 2005; Shi
et al., 2016). Although predicting AML patient response to
drugs based on cellular metabolic profiles remains elusive,
these observations point towards a key role of FA metabolism,
particularly increased β-oxidation. This might explain why
obesity is a leading risk factor for most cancers (Lichtman, 2010).
In the context of leukaemia, excess adipose tissue increases the
risk of disease onset (Naveiras et al., 2009) and is associated
with poorer outcome due to chemotherapy resistance (Behan
et al., 2009; Ye et al., 2016). Coupled with these findings is the
increased proportion of adipose tissue in the bone marrow as
people age, which incidentally correlates with increased rates of
disease incidence (Stenderup et al., 2003). Taken together, the
accumulation of bone marrow adipose tissue and incidence of
obesity represent probable risk factors for acquiring AML and
subsequent therapy resistance.
Based on these findings, efforts have been made to target
FA metabolism as a therapeutic strategy. For instance, the FA
uptake protein CD36 has been evaluated as a potential target.
Sulfo-N-succinimidyl oleate (SSO) is a FA analogue that inhibits
CD36 function (Kuda et al., 2013) and has been shown to
perturb cell growth in vitro (Coort et al., 2002) and reduce
CPT1 activity (Campbell et al., 2004). However, its toxicity in
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vivo deems SSO unsuitable for therapeutic use. As an alternative
strategy, inhibitory CD36-specific antibodies increase sensitivity
of chronic myelogenous leukaemia cells to the first-line drug
imatinib (Landberg et al., 2018). Etomoxir irreversibly inhibiting
CPT1 and thus ß-oxidation (Abdel-aleem et al., 1994) and has
been successfully used for the treatment of cardiac conditions
(Bristow, 2000). In AML, etomoxir sensitises cells to apoptosis-
inducing treatments (Samudio et al., 2010). Another CPT1
inhibitor, ST1326, was shown to inhibit proliferation, survival
and chemoresistance in leukaemia cell lines and primary cells
by driving cells to apoptosis and causing toxic accumulation
of cytosolic palmitate (Ricciardi et al., 2015). Collectively,
these studies indicate that inhibition or reversal of increased
FA oxidation has been shown to be a suitable therapeutic
intervention, in particular when combined with other cytotoxic
drugs.
OUTLOOK AND CONCLUSION
FA metabolism is up-regulated in many cancer types, such
as colorectal (Zhou et al., 2013), ovarian (Wang et al.,
2005), and glioblastoma (Beckner et al., 2009). Metabolic
adaptations of leukaemia cells to the microenvironment
contribute to proliferation and disease progression (Samudio
et al., 2010). Cancer cells develop resistance in part by
increasing FA oxidation and thus, not surprisingly, obesity
is emerging as a major risk factor. This provides rational
for supportive therapeutic measures through nutritional
intervention.
At present, it is not clear to which extent metabolic
adaptations of cancer cells are either stable or transient. Future
investigations will need to explore how epigenetic mechanisms
regulate and sustain metabolic states in healthy cells and also
how cancers cells adapt to their microenvironment. Promising
initial studies that have investigated the dependence of cancer
cells on FA oxidation warrant follow-up in pre-clinical models,
in particular as part of combinatorial therapies.
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